



ANF
2024

MARCH 21-24, 2024

13th
ADRIATIC
NEUROLOGY
FORUM

Park Plaza Histria
PULA / Croatia

SCIENTIFIC
PROGRAM

ANF 2024

Dear colleagues, dear friends!

It is our pleasure to cordially invite you to join the 13th Adriatic Neurology Forum which will be held in Pula, Croatia, from 21st March to 24th March 2024.

ANF is a traditional gathering of neurologists from the region and, as in previous years, we plan to offer you a spectrum of exquisite lectures by some of the top experts in the field of Epilepsy, Multiple sclerosis and Neurodegenerative diseases enriched with some hot topics in Cephalgia, Intensive care.

Traditionally, we invite and encourage our younger colleagues to present their scientific and professional work at the “Young Neurologists Forum”, which is an important part of the ANF.

As every year, we did not forget the social component, which is very important from the very beginning of the ANF. Besides interesting lectures we also guarantee you good social program and a time schedule which will allow you to enjoy all charms of Pula.

We look forward welcoming you in Pula!

Organizing Committee ANF 2024



CONGRESS ORGANIZER

Udruga Neuronet

ORGANIZING COMMITTEE

Silvio Bašić
 Dragoslav Sokić
 Davor Sporiš

Ranko Raičević
 Aleksandar Ristić
 Tomislav Babić

SCIENTIFIC COMMITTEE

Tomislav Babić
 Silvio Bašić
 Vanja Bašić Kes
 Fran Borovečki
 Krešimir Čaljkušić
 Mario Habek
 Stjepan Jurić
 Šarlota Mesaroš
 Milija Mijajlović
 Igor Petrović

Zdravka Poljaković Skurić
 Ranko Raičević
 Aleksandar Ristić
 Marina Roje Bedeković
 Dragoslav Sokić
 Davor Sporiš
 Marina Svetel
 Marina Titlić
 Vladimira Vuletić

GENERAL INFORMATION**Venue**

Hotel Park Plaza Histria, Pula

Date

March 21- 24, 2024

Registration fee

400 €

Congress languages

English and Croatian

Accreditation

The Congress will be scored in accordance with the regulations on continuous education by Croatian Medical Chamber.

THURSDAY, 21st March 2024

15:00 Registration
 17:00 OPENING CEREMONY

17:15-20:00 CEREBROVASCULAR DISEASE AND INTENSIVE CARE**Chairs: Poljaković Skurić Z., Čaljkušić K., Crnjaković M.**

17:15-17:35 Poljaković Skurić Z.: The first Croatian stroke registry - what have we done so far?
 17:35-17:55 Matijević V.: Reversible vasoconstriction syndrome - pitfalls and dilemmas
 17:55-18:15 Čaljkušić K.: Medullary stroke
 18:15-18:35 Crnjaković M.: Intracranial pressure, more than a number
 18:35-18:55 Bonifačić D.: Heparin-induced thrombocytopenia in neurological diseases treated with unfractionated heparin
 18:55-19:15 Mišir M.: Transverse myelitis in the neurological ICU
 19:15-19:35 Drnasin S.: Intracranial pressure monitoring
 19:35-20:00 DISCUSSION


FRIDAY, 22nd March 2024**09:00-13:55 MULTIPLE SCLEROSIS****Chairs: Lazibat I., Mesaroš Š., Habek M.**

09:00-09:20 Lazibat I.: Challenges in the treatment of multiple sclerosis – expectations and new perspectives
 09:20-09:40 Bašić Kes V.: MS – female reproductive function
 09:40-10:00 Mesaroš Š.: MR in NMOSD/MOGAD
 10:00-10:20 Habek M.: Sexual dysfunction in MS and other neurological disorders
 10:20-10:40 Adamec I.: Urogenital dysfunction in MS and other neurological disorders
 10:40-11:00 DISCUSSION



Lamal[®]

25 mg, 50 mg, 100 mg i 200 mg tablete
lamotriginum



OGI-054-01-10-2023-HR

SAMO ZA ZDRAVSTVENE RADNIKE

Napomena: Prije propisivanja lijeka Lamal pročitajte odobreni Sažetak opisa svojstva lijeka. Sastavni dio ovog promidžbenog materijala predstavljaju i cjelokupni odobreni Sažetak opisa svojstava lijeka te odobrena Uputa o lijeku, dostupni na internetskoj stranici Agencije za lijekove i medicinske proizvode (www.halmed.hr), sve sukladno člancima 14,15 i 24 Pravilnika o načinu oglašavanja o lijekovima (Narodne novine broj 43/15). **Način i mjesto izdavanja:** na recept, u ljekarni. Brojevi odobrenja za stavljanje lijeka u promet: Lamal 25 mg tablete: HR-H-345118531, Lamal 50 mg tablete: HR-H-280480559, Lamal 100 mg tablete: HR-H-338019615, Lamal 200 mg tablete: HR-H-889804751. **Nositelj odobrenja za stavljanje lijekova u promet:** Alkaloid d.o.o., Slavonska avenija 6 A, 10 000 Zagreb. **Datum sastavljanja:** listopad 2023.




ALKALOID
Health above all

11:00-11:30 Break

11:30-12:10 Successful treatment of multiple sclerosis - Meet the Expert (Symposium by Novartis)
Speakers: Habek M., Gabelić T.

12:10-12:55 OCREVUS - A decade behind us - experiences and challenges in a large hospital system (Symposium by Roche)
Speakers: Lazibat I., Stojić M., Badžak J., Majdak M.

12:55-13:55 Early use of MAVENCLAD[®] in the treatment of RMS (Symposium by Merck)
Speakers: Barun B., Lazibat I., Kidemet Piskač S.

13:55-14:55 Lunch/Break

15:00-17:15 **CEPHALEA**

Chairs: Titlić M., Mijajlović M., Stojić M.

15:00-15:20 Mijajlović M.: Medication overuse headache: recommendations for new therapeutic strategies

15:20-15:40 Stojić M.: Diagnosis and management of migraine in young people

15:40-16:00 Titlić M.: Cluster headache

16:00-16:20 Bačić Baronica K.: Non painful symptoms of migraine – importance and treatment

16:20-16:40 DISCUSSION


16:40-17:00 Beat the migraine with just 1 dose every 4 weeks (Symposium by Novartis)
Speakers: Titlić M., Petravić D., Stojić M., Bačić Baronica K.,

17:00 - 17:15 Evolution of the therapeutic approach in migraine prevention (Symposium by Abbvie)
Speaker: Majdak M.

17:15 FREE AFTERNOON

LYVAM®

250 mg, 500 mg, 750 mg i 1000 mg filmom obložene tablete
levetiracetamum



OGL-139-02-10-2023-HR

SAMO ZA ZDRAVSTVENE RADNIKE

Napomena: Prije propisivanja lijeka Lyvam pročitajte odobreni Sažetak opisa svojstva lijeka. Sastavni dio ovog promidžbenog materijala predstavljaju i cjelokupni odobreni Sažetak opisa svojstava lijeka te odobrena Uputa o lijeku, dostupni na internetskoj stranici Agencije za lijekove i medicinske proizvode (www.halmed.hr), sve sukladno člancima 14,15 i 24 Pravilnika o načinu oglašavanja o lijekovima (Narodne novine broj 43/15). **Način i mjesto izdavanja:** na recept, u ljekarni. **Brojevi odobrenja za stavljanje lijeka u promet:** Lyvam 250 mg filmom obložene tablete: HR-H-653401273; Lyvam 500 mg filmom obložene tablete: HR-H-182178850; Lyvam 750 mg filmom obložene tablete: HR-H-502777166; Lyvam 1000 mg filmom obložene tablete: HR-H-732973736. **Nositelj odobrenja za stavljanje lijekova u promet:** Alkaloid d.o.o., Slavonska avenija 6 A, 10 000 Zagreb, Hrvatska. **Datum sastavljanja:** listopad 2023.




ALKALOID
Health above all

SATURDAY, 23rd March 2024

09:00-13:05 MOVEMENT DISORDERS AND DEMENTIA

Chairs: Borovečki F., Svetel M., Bago Rožanković P.

- 09:00-09:20** Svetel M.: Interplay between focal epilepsies and focal dystonias
- 09:20-09:40** Borovečki F.: Personalized medicine in the diagnosis and treatment of neurodegenerative diseases
- 09:40-10:00** Bago Rožanković P.: Monotherapy with infusion based treatment of Parkinsons disease – useful or not?
- 10:00-10:20** Petrović I: Immune-mediated involuntary movements
- 10:20-10:40** Klepac N.: Hope and questions raised by new treatments for Alzheimer's diseases
- 10:40-11:00** Badžak J.: An unusual case series of Creutzfeldt-Jacob disease
- 11:00-11:20** DISCUSSION

11:20-11:50 Break

11:50-13:05 PRODUODOPA - a new way of treating advanced Parkinson's disease (Symposium by Abbvie)

Moderator: Borovečki F.

- Merćep I.: Foslevodopa/foscarbidopa - introduction to research
- Borovečki F.: PRODUODOPA - possibilities and evidence of a new way of treating advanced Parkinson's disease
- Bago Rožanković P.: What does 24-hour continuous administration of levodopa mean for your patients?
- Vojnović V.: Application of a subcutaneous infusion delivery system

13:05-13:50 Brivaracetam in clinical practice (Symposium by Medis)

- Sporiš D.: The role of brivaracetam in everyday clinical practice
- Poljaković-Skurić Z.: Brivaracetam in the clinical practice of intensive care medicine
- Jurić S.: Brivaracetam - a step forward in the treatment of drug-resistant epilepsy



PRODUODOPA®

240 mg/ml + 12 mg/ml otopina za infuziju
foslevodopa/foskarbidopa

13:50-14:50 Lunch/Break

14:50-16:30 YOUNG NEUROLOGISTS FORUM I

Chairs: Ristić A., Bašić I., Petrović I.

- 14:50-15:00** Šarić Jurić J.: The effect of CPAP on the recovery of cognitive functions in patients with obstructive sleep apnea
- 15:00-15:10** Ždraljević M.: Impact of atrial fibrillation on the outcome of acute ischemic stroke
- 15:10-15:20** Chudy H.: The effect of 24-hour use of the lecion pump on dyskinesias
- 15:20-15:30** Vukojević M.: Mediterranean myoclonus: 3 case reports of Unferricht-Lundborg disease
- 15:30-15:40** Radišić V.: Neurological manifestations of acute intermittent porphyria
- 15:40-15:50** Markulin I.: Respiratory insufficiency as the first manifestation of neuromuscular disease
- 15:50-16:00** Bajunović A.: Dural arteriovenous fistula as a cause of intracerebral hemorrhage - case report
- 16:00-16:10** Polegubić M.: The importance of patient cooperation in epilepsy treatment planning – pharmacoresistance YES or NO
- 16:10-16:30** DISCUSSION

16:30-18:50 EPILEPSY

Chair: Bašić S., Sokić D., Sporiš D.

- 16:30-16:50** Ristić A.: Pharmacoresistant epilepsy
- 16:50-17:10** Bašić S.: Next step in epilepsy treatment - disease modifying therapy
- 17:10-17:30** Sokić D.: Advantages and disadvantages of VNS
- 17:30-17:50** Sporiš D.: Stereo-EEG for minimally invasive surgery
- 17:50-18:10** Chudy D.: Deep brain stimulation in the treatment of pharmacoresistant epilepsies.
- 18:10-18:30** Malenica M., Sruk A.: Lennox-Gastaut syndrome from the perspective of neurologists and neuropediatricians - have we missed something? (Sponsored lecture by Swixx)
- 18:30-18:50** DISCUSSION

notes

SUNDAY, 24th March 2024

9:00-11:00 YOUNG NEUROLOGISTS FORUM II

Chair: Klepac N., Sruk A., Županić S.

09:00-09:10 Božović I.: A quick guide through idiopathic inflammatory myopathies

09:10-09:20 Popović Z.: The role of PACAP in the pathophysiology of primary headaches

09:20-09:30 Mihajilović I.: Anti-NMDA encephalitis - case report

09:30-09:40 Pečvarac V.: Treatment of chronic migraine

09:40-09:50 Matoša S.: Neurogenic orthostatic hypotension

09:50-10:00 Momčilović N.: CLIPPERS – case report

10:00-10:10 Hero M.: LGI1 autoimmune encephalitis – case report

10:10-10:20 Kordić J.: Focal status epilepticus of occipital origin

10:20-10:30 Mioč M.: Narcolepsy diagnostic challenges

10:30-10:40 Mamić M.: Oculomotor nerve palsy caused by an unruptured aneurysm - case report

10:40-11:00 DISCUSSION

11:00 CLOSING REMARKS



notes

GOLD sponsor

abbvie

SILVER sponsor

 NOVARTIS

SPONSORS


ALKALOID
Health above all

 BELUPO

 BERLIN-CHEMIE
MENARINI

 makpharm

 MEDIS

MERCK

 PHOENIX
Farmacija d.o.o.
a PHOENIX company

 Pfizer

 PLIVA | teva

 Roche

 STADA
Our Mission - Your Health

 Swixx BioPharma



Vivid Original

PRIJAVE I INFORMACIJE

Vivid Original d.o.o.

Maksimirska 112A, 10000 Zagreb

Iva Šimunić

iva.simunic@vivid-original.com

+385 91 333 07 33